CIK 0001590877 · Non-accelerated filer<br>Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 471851754
- Phone
- 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- Open-market buys, last 90 days
- $949,381
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$949,381. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-02 | Danos Olivier Chief Scientific Officer | Grant or award · Stock Options (Right to buy) | +95,721 | 95,721 | ||
| 2025-01-02 | Simpson Curran Chief Executive Officer | Shares withheld for taxes | −11,917 | $7.73 | $92K | 158,120 |
| 2025-01-02 | Simpson Curran Chief Executive Officer | Grant or award | +98,912 | 257,032 | ||
| 2025-01-02 | Simpson Curran Chief Executive Officer | Grant or award · Stock Options (Right to buy) | +476,606 | 476,606 | ||
| 2025-01-02 | Chan Mitchell Chief Financial Officer | Grant or award · Stock Options (Right to buy) | +62,547 | 62,547 | ||
| 2025-01-02 | Christmas Patrick J. Chief Legal Officer | Shares withheld for taxes | −11,395 | $7.73 | $88K | 160,810 |
| 2025-01-02 | Christmas Patrick J. Chief Legal Officer | Grant or award · Stock Options (Right to buy) | +223,350 | 223,350 | ||
| 2024-10-01 | KARABELAS ARGERIS N Director | Option exercise 10b5-1 | +10,000 | $3.76 | $38K | 21,286 |
| 2024-10-01 | KARABELAS ARGERIS N Director | Sale 10b5-1 | −10,000 | $10.11 | $101K | 11,286 |
| 2024-10-01 | KARABELAS ARGERIS N Director | Option exercise · Stock Options (Right to Buy) 10b5-1 | −10,000 | 0 | ||
| 2024-09-16 | Chan Mitchell Chief Financial Officer | Grant or award | +58,869 | 58,869 | ||
| 2024-09-16 | Chan Mitchell Chief Financial Officer | Grant or award · Stock Options (Right to buy) | +289,362 | 289,362 | ||
| 2024-09-03 | KARABELAS ARGERIS N Director | Option exercise 10b5-1 | +10,000 | $3.76 | $38K | 21,286 |
| 2024-09-03 | KARABELAS ARGERIS N Director | Sale 10b5-1 | −9,300 | $11.50 | $107K | 11,986 |
| 2024-09-03 | KARABELAS ARGERIS N Director | Sale 10b5-1 | −700 | $12.34 | $9K | 11,286 |
| 2024-09-03 | KARABELAS ARGERIS N Director | Option exercise · Stock Options (Right to Buy) 10b5-1 | −10,000 | 10,000 | ||
| 2024-08-08 | Mills Kenneth T. Director | Option exercise | +36,316 | $0.85 | $31K | 444,351 |
| 2024-08-08 | Mills Kenneth T. Director | Option exercise · Stock Options (Right to Buy) | −36,316 | 0 | ||
| 2024-08-01 | PAKOLA STEVE Chief Medical Officer | Grant or award | +58,386 | 165,578 | ||
| 2024-08-01 | Christmas Patrick J. Chief Legal Officer | Grant or award | +56,446 | 172,205 |
Page 6 of 11 · 216 trades